Highlights
IIA supported (ever)1 patent
About
Next Generation Treatment of Pancreatic Cancer
Xerient is focused on unmet needs in cancer treatment, particularly in abdominal and gastrointestinal cancers. Xerient is pursuing the development of novel therapeutics and diagnostic technologies that can dramatically improve the survival of these patients.
The company is introducing a portfolio of products that will address hard to treat cancers in the abdominal/GI area, beginning with solutions for pancreatic cancer.
Identity
| Name | Xerient |
|---|---|
| Slug | xerient |
| Type / kind | startup |
| Source _id | Kw74RPHdxHkwFBivyh6qxmmsrJW25PeJdAjECyfrkJIcVuqANTnKzi |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country | Israel |
|---|---|
| HQ country code | IL |
| HQ city | Petah Tikva |
| HQ address | Petah Tikva, Israel |
Web & social
| Website | https://xerient.net/ |
|---|---|
| https://www.linkedin.com/company/56424827 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesHealthcareProviders
Business models
B2B
Tags
gastroenterologycancerpharmaceuticalscancer-therapy
Funding
| Total raised | $5.0M |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}